← Eichor
Condition: Inflammatory Myositis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Inflammatory Myositis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammato
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06599411A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542Optimizing Treatment on Idiopathic Inflammatory Myopathies
Phase N/A · 1 location(s) · University of Sao Paulo · NCT03092180Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis
Phase 2/Phase 3 · 2 location(s) · Restem, LLC. · NCT07160205A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT06980597Natural History of Inflammatory Muscle Diseases
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT05738824Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Peking University Third Hospital · NCT06828042Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University General Hospital · NCT07022197Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT05251415A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants Wit
Phase 1 · 37 location(s) · AstraZeneca · NCT06916806GC012F Injection in Refractory Idiopathic Inflammatory Myopathy
EARLY_Phase 1 · 1 location(s) · Daishi Tian · NCT07086404A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Phase 1 · 19 location(s) · GlaxoSmithKline · NCT07371468Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Phase 2 · 8 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT07103746CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathie
Phase 3 · 146 location(s) · Pfizer · NCT05895786A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
Phase 1 · 1 location(s) · iCell Gene Therapeutics · NCT07715136A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06978647Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositi
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT00059748CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06941129A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease
Phase 1 · 28 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07115745A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With
Phase 1 · 14 location(s) · Allogene Therapeutics · NCT07085104An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
NA · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06379646Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06614270Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Diseas
Phase N/A · 1 location(s) · Hospital Universitario Araba · NCT07249060Search for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory Myopathies
NA · 1 location(s) · University Hospital, Strasbourg, France · NCT04917705OM336 in Seropositive Autoimmune Diseases
Phase 1 · 1 location(s) · Lakefront Biotherapeutics West LLC · NCT07229144Adult Autoimmune Myopathies (MAIA)
NA · 1 location(s) · University Hospital, Brest · NCT04792931MTS109 in Patients With Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT07526350Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
EARLY_Phase 1 · 2 location(s) · Austin Neuromuscular Center · NCT06479863
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.